BGB-A317-306
Completed
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeOne Study ID
ClinicalTrials.gov ID
EudraCT Number
China Drug Trials ID
Study Overview
Sex:
All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No
Study Documents
Study Protocol Statistical Analysis Plan Plain Language SummaryStudy Overview
Sex:
All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No